William H. Polonsky
University of California, San Diego
172 Papers
351 Citations
William H. Polonsky is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 40, co-authored 138 publications. Previous affiliations of William H. Polonsky include Joslin Diabetes Center.
Chat about Author
Papers
Assessment of diabetes-related distress.
William H. Polonsky,Barbara J. Anderson,Patricia A Lohrer,Garry Welch,Alan M. Jacobson,Jennifer E Aponte,Carolyn E. Schwartz +6 more
TL;DR: High internal reliability and consistent pattern of correlational findings indicates that the PAID is tapping into relevant aspects of emotional distress and that its particular feature, the measurement of diabetes-related emotional distress, is uniquely associated with diabetes-relevant outcomes.
1.4K
Assessing psychosocial distress in diabetes: development of the diabetes distress scale.
William H. Polonsky,Lawrence Fisher,Jay Edward Earles,R. James Dudl,Joel Lees,Joseph T. Mullan,Richard A. Jackson +6 more
TL;DR: The Diabetes Distress Scale has a consistent, generalizable factor structure and good internal reliability and validity across four different clinical sites, and may serve as a valuable measure of diabetes-related emotional distress for use in research and clinical practice.
1.3K
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Roy W. Beck,Tonya D Riddlesworth,Katrina J. Ruedy,Andrew J. Ahmann,Richard M. Bergenstal,Stacie Haller,Craig Kollman,Davida F. Kruger,Janet B. McGill,William H. Polonsky,Elena Toschi,Howard Wolpert,David Price +12 more
TL;DR: Among adults with type 1 diabetes who used multiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decrease in HbA1c level during 24 weeks.
The Problem Areas in Diabetes Scale: An evaluation of its clinical utility
TL;DR: The study findings provided support for the construct validity of the PAID, including evidence for discriminant validity from its ability to detect differences between IDDM and NIDDM treatment groups expected to differ in the emotional impact of life with diabetes.
658
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
TL;DR: Specific barriers to medication adherence in T2D, especially those that are potentially modifiable, need to be more clearly identified and strategies that target poor adherence should focus on reducing medication burden and addressing negative medication beliefs of patients.